Drug Profile
AP 22408
Alternative Names: Signal transduction inhibitor - Ariad/Aventis; Src inhibitor - Ariad/AventisLatest Information Update: 17 Feb 2017
Price :
$50
*
At a glance
- Originator ARIAD Pharmaceuticals
- Class Osteoporosis therapies
- Mechanism of Action Src-Family kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Postmenopausal osteoporosis